$ATHA
Athira Pharma, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017421 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.168M $8.766M $8.927M
YoY Change 0.69% 90.03% 167.28%
% of Gross Profit
Research & Development $16.97M $14.80M $14.46M
YoY Change 58.45% 23.11% 94.22%
% of Gross Profit
Depreciation & Amortization $231.0K $221.0K $154.0K
YoY Change 87.8% 87.29% 37.5%
% of Gross Profit
Operating Expenses $16.97M $14.80M $14.46M
YoY Change 58.45% 23.11% 94.22%
Operating Profit -$24.13M -$23.57M -$23.39M
YoY Change 35.38% 41.67% 116.93%
Interest Expense $985.0K $493.0K $2.000K
YoY Change 98400.0% 566.22% -97.5%
% of Operating Profit
Other Income/Expense, Net $985.0K $493.0K $173.0K
YoY Change 1249.32% 566.22% 105.95%
Pretax Income -$20.19M -$24.34M -$20.98M
YoY Change 28.81% 74.14% 136.53%
Income Tax
% Of Pretax Income
Net Earnings -$20.19M -$24.34M -$20.98M
YoY Change 28.81% 74.14% 136.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.53 -$0.65 -$0.56
Diluted Earnings Per Share -$0.53 -$646.0K -$558.1K
COMMON SHARES
Basic Shares Outstanding 37.82M 37.64M 37.62M
Diluted Shares Outstanding 37.82M 37.67M 37.59M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $221.0M $252.4M $263.5M
YoY Change -6.28% -11.42% -13.37%
Cash & Equivalents $87.05M $95.06M $117.8M
Short-Term Investments $133.9M $157.3M $145.7M
Other Short-Term Assets $6.310M $3.456M $3.394M
YoY Change 454.48% 16.44% -24.58%
Inventory
Prepaid Expenses
Receivables $1.700M $0.00 $2.234M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $229.0M $255.9M $269.2M
YoY Change -4.19% -11.92% -13.61%
LONG-TERM ASSETS
Property, Plant & Equipment $4.291M $4.294M $4.354M
YoY Change 40.18% 47.26% 50.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $39.07M $29.84M $37.64M
YoY Change -62.3% -54.04% -29.64%
Other Assets $55.00K $155.0K $225.0K
YoY Change -56.0% -31.11% 309.09%
Total Long-Term Assets $45.21M $36.15M $43.85M
YoY Change -58.27% -48.08% -24.2%
TOTAL ASSETS
Total Short-Term Assets $229.0M $255.9M $269.2M
Total Long-Term Assets $45.21M $36.15M $43.85M
Total Assets $274.2M $292.0M $313.0M
YoY Change -21.06% -18.91% -15.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $751.0K $605.0K $1.431M
YoY Change -21.69% -48.11% -15.17%
Accrued Expenses $9.197M $8.780M $7.743M
YoY Change 12.87% 41.5% 196.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.26M $9.692M $9.471M
YoY Change 9.35% 26.96% 110.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.672M $1.754M $1.554M
YoY Change -2.11% -1.52% -8.59%
Total Long-Term Liabilities $1.672M $1.754M $1.554M
YoY Change -2.11% -1.52% -8.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.26M $9.692M $9.471M
Total Long-Term Liabilities $1.672M $1.754M $1.554M
Total Liabilities $11.94M $11.45M $11.03M
YoY Change 7.59% 21.57% 77.91%
SHAREHOLDERS EQUITY
Retained Earnings -$161.4M -$141.2M -$116.9M
YoY Change 102.87% 134.18%
Common Stock $426.1M $423.7M $420.3M
YoY Change 2.48% 1.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $262.2M $280.6M $302.0M
YoY Change
Total Liabilities & Shareholders Equity $274.2M $292.0M $313.0M
YoY Change -21.06% -18.91% -15.27%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$20.19M -$24.34M -$20.98M
YoY Change 28.81% 74.14% 136.63%
Depreciation, Depletion And Amortization $231.0K $221.0K $154.0K
YoY Change 87.8% 87.29% 37.5%
Cash From Operating Activities -$21.64M -$18.59M -$16.57M
YoY Change 110.12% 154.24% 126.86%
INVESTING ACTIVITIES
Capital Expenditures -$244.0K -$151.0K $745.0K
YoY Change 90.62% 27.97% 145.07%
Acquisitions
YoY Change
Other Investing Activities $13.88M -$4.310M $24.59M
YoY Change -198.61% -137.27% -209.78%
Cash From Investing Activities $13.63M -$4.461M $23.85M
YoY Change -196.01% -138.94% -205.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 297.0K 210.0K
YoY Change -100.0% -214.67% -99.78%
NET CHANGE
Cash From Operating Activities -21.64M -18.59M -16.57M
Cash From Investing Activities 13.63M -4.461M 23.85M
Cash From Financing Activities 0.000 297.0K 210.0K
Net Change In Cash -8.008M -22.75M 7.484M
YoY Change -67.14% -685.54% -88.86%
FREE CASH FLOW
Cash From Operating Activities -$21.64M -$18.59M -$16.57M
Capital Expenditures -$244.0K -$151.0K $745.0K
Free Cash Flow -$21.40M -$18.44M -$17.32M
YoY Change 110.36% 156.31% 127.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
Bothell,
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001620463
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39503
dei Entity Registrant Name
EntityRegistrantName
Athira Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3368487
dei Entity Address Address Line1
EntityAddressAddressLine1
18706 North Creek Parkway,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 104
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98011
dei City Area Code
CityAreaCode
425
dei Local Phone Number
LocalPhoneNumber
620-8501
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ATHA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37817724
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95057000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110537000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
157347000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
143222000
CY2021Q4 atha Unbilled Grant Receivable Current
UnbilledGrantReceivableCurrent
2336000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3456000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4704000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
255860000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
260799000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
210000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4294000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3757000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1648000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1460000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
29844000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
65936000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56000
CY2022Q2 us-gaap Assets
Assets
292011000
CY2021Q4 us-gaap Assets
Assets
332008000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
605000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
567000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8780000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8437000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
307000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
288000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9692000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9292000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1754000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1632000
CY2022Q2 us-gaap Liabilities
Liabilities
11446000
CY2021Q4 us-gaap Liabilities
Liabilities
10924000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37817724
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37817724
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37379077
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37379077
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
423696000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
417363000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1925000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-388000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141210000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95895000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
280565000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
321084000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292011000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
332008000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14803000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12024000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29263000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19469000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8766000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4613000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17693000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7949000
us-gaap Variable Lease Cost
VariableLeaseCost
40000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13974000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
350709000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
23569000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
16637000
us-gaap Costs And Expenses
CostsAndExpenses
46956000
us-gaap Costs And Expenses
CostsAndExpenses
27418000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23569000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16637000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46956000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27418000
CY2022Q2 atha Grant Income
GrantIncome
-1259000
CY2021Q2 atha Grant Income
GrantIncome
2589000
atha Grant Income
GrantIncome
975000
atha Grant Income
GrantIncome
4420000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
74000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
666000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
158000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24335000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-13974000
us-gaap Net Income Loss
NetIncomeLoss
-45315000
us-gaap Net Income Loss
NetIncomeLoss
-22840000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-469000
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
9000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1537000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24804000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13965000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46852000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22836000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37667971
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37214602
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37630856
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36499004
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
274282000
CY2021Q1 atha Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits
70000
CY2021Q1 atha Issuance Of Common Stock Value During Period Follow On Public Offering Net Of Underwriters Discounts And Commissions
IssuanceOfCommonStockValueDuringPeriodFollowOnPublicOfferingNetOfUnderwritersDiscountsAndCommissions
96762000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
974000
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-8866000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
363217000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
119000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
229000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1109000
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
9000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110537000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
321084000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
210000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2731000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1068000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20980000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
301977000
CY2022Q2 atha Issuance Of Common Stock Upon Exercise Of Common Stock Options And Vesting Of Restricted Stock Units
IssuanceOfCommonStockUponExerciseOfCommonStockOptionsAndVestingOfRestrictedStockUnits
83000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
214000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3095000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-469000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24335000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
280565000
us-gaap Profit Loss
ProfitLoss
-45315000
us-gaap Profit Loss
ProfitLoss
-22840000
us-gaap Share Based Compensation
ShareBasedCompensation
5826000
us-gaap Share Based Compensation
ShareBasedCompensation
2083000
us-gaap Depreciation
Depreciation
375000
us-gaap Depreciation
Depreciation
230000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
92000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
68000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-149000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-226000
atha Increase Decrease In Unbilled Grant Receivables
IncreaseDecreaseInUnbilledGrantReceivables
-2336000
atha Increase Decrease In Unbilled Grant Receivables
IncreaseDecreaseInUnbilledGrantReceivables
1289000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1149000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3217000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
365000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3318000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-139000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
365000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35162000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14622000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
51670000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
173563000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
71951000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
152740000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
9988000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
896000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
418000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19385000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11253000
atha Proceeds From Exercise Of Common Stock Options
ProceedsFromExerciseOfCommonStockOptions
507000
atha Proceeds From Exercise Of Common Stock Options
ProceedsFromExerciseOfCommonStockOptions
189000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
96762000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
507000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96951000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15270000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71076000
atha Proceeds From Issuance Of Convertible Preferred Stock And Common Stock Warrants
ProceedsFromIssuanceOfConvertiblePreferredStockAndCommonStockWarrants
407400000
CY2022Q2 atha Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
282200000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60625000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95267000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131701000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
680000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1. Description of Business</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc. (the “Company”) was incorporated as M3 Biotechnology, Inc. in the state of Washington on </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">March 31, 2011</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> and reincorporated in the state of Delaware on </span><span style="font-size:10.0pt;font-family:Arial;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">October 27, 2015</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">. In April 2019, the Company changed its name to Athira Pharma, Inc. The Company currently has office and laboratory space in Bothell and Seattle, Washington. The Company is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Since the Company’s inception, it has funded its operations primarily with proceeds from the sale and issuance of common stock, convertible preferred stock, common stock warrants, and convertible notes, and to a lesser extent from grant income and stock option exercises. From the Company’s inception through June 30, 2022, it has raised aggregate net cash proceeds of $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">407.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million primarily from the issuance of its common stock, convertible preferred stock, common stock warrants, and convertible notes. As of June 30, 2022, the Company had $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">282.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million in cash, cash equivalents and investments and had not generated positive cash flows from operations. Since the Company’s inception, it has devoted substantially all of its resources to its research and development efforts such as small molecule compound discovery, nonclinical studies and clinical trials, as well as manufacturing activities, establishing and maintaining the Company’s intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Based upon the Company’s current operating plan, it estimates that its $</span><span style="font-size:10.0pt;font-family:Arial;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">282.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> million of cash, cash equivalents and investments at June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements through at least the 12 months following the date of this report.</span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2011-03-31
atha Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-10-27
CY2022Q2 atha Cash Cash Equivalents And Short Term And Long Term Investments
CashCashEquivalentsAndShortTermAndLongTermInvestments
282200000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95057000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110537000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
210000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95267000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110537000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates include those used for fair value of assets and liabilities, accrued liabilities, valuation allowance for deferred tax assets, and stock-based compensation. Management evaluates related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5192000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4280000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
898000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
523000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4294000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3757000
CY2022Q2 us-gaap Depreciation
Depreciation
221000
us-gaap Depreciation
Depreciation
375000
CY2021Q2 us-gaap Depreciation
Depreciation
118000
us-gaap Depreciation
Depreciation
230000
CY2022Q2 atha Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5098000
CY2021Q4 atha Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5723000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1759000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1907000
CY2022Q2 atha Accrued Professional Services And Other Current
AccruedProfessionalServicesAndOtherCurrent
1923000
CY2021Q4 atha Accrued Professional Services And Other Current
AccruedProfessionalServicesAndOtherCurrent
807000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8780000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8437000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
493000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
74000
us-gaap Interest And Other Income
InterestAndOtherIncome
668000
us-gaap Interest And Other Income
InterestAndOtherIncome
158000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
493000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
74000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
666000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
158000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
228000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
466000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
480000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
494000
CY2022Q2 atha Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
856000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2524000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
463000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2061000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
88000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
85000
us-gaap Operating Lease Expense
OperatingLeaseExpense
177000
us-gaap Operating Lease Expense
OperatingLeaseExpense
146000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
41000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
20000
us-gaap Variable Lease Cost
VariableLeaseCost
85000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9500018
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7695922
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8306000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3095000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1109000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5826000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2083000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0080
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9278
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8934
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
atha Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
15700000
atha Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
10200000
atha Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue
129000
atha Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantDateFairValue
67000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4442315
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
1868953
atha Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Unit Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitGranted
1998047
atha Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Forfeited Cancelled Or Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsForfeitedCancelledOrExpired
143233
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4456454
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2270896
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1985797
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.43
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
288457
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
129233
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.26
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3839003
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M25D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
793000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2957147
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y2M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
204000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
881856
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.42
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M25D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
589000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
297000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1300000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
22100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3839003
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
881856
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4083678
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2489446
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36499004
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63

Files In Submission

Name View Source Status
0000950170-22-017421-index-headers.html Edgar Link pending
0000950170-22-017421-index.html Edgar Link pending
0000950170-22-017421.txt Edgar Link pending
0000950170-22-017421-xbrl.zip Edgar Link pending
atha-20220630.htm Edgar Link pending
atha-20220630.xsd Edgar Link pending
atha-ex31_1.htm Edgar Link pending
atha-ex31_2.htm Edgar Link pending
atha-ex32_1.htm Edgar Link pending
atha-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img104320290_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
atha-20220630_def.xml Edgar Link unprocessable
atha-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atha-20220630_htm.xml Edgar Link completed
atha-20220630_pre.xml Edgar Link unprocessable
atha-20220630_cal.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending